Search Result "EMPA-REG OUTCOME trial"
SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
Journal: Current Cardiology Reviews
Volume: 16 Issue: 4 Year: 2020 Page: 258-265
Author(s): Georgios Kyriakos,Lourdes V. Quiles-Sanchez,Anna Garmpi,Paraskevi Farmaki,Konstantina Kyre,Spyridon Savvanis,Vasileios K. Antoniou,Eleni Memi
Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Journal: Current Vascular Pharmacology
Volume: 15 Issue: 5 Year: 2017 Page: 457-468
Author(s): C. Tsioufis,E. Andrikou,C. Thomopoulos,N. Papanas,D. Tousoulis
Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
Journal: Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume: 21 Issue: 9 Year: 2021 Page: 1555-1589
Author(s): Georgios S. Papaetis
Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
Journal: Current Diabetes Reviews
Volume: 16 Issue: 9 Year: 2020 Page: 917-921
Author(s): Samit Ghosal,Binayak Sinha
SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature
Journal: Current Pharmaceutical Design
Volume: 23 Issue: 10 Year: 2017 Page: 1510-1521
Author(s): Konstantinos Imprialos,Charles Faselis,Chrysoula Boutari,Konstantinos Stavropoulos,Vasilios Athyros,Asterios Karagiannis,Michael Doumas
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management
Journal: Current Pharmaceutical Design
Volume: 23 Issue: 10 Year: 2017 Page: 1522-1532
Author(s): Niki Katsiki,Dimitri P. Mikhailidis,Michael J. Theodorakis
Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure
Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 18 Issue: 2 Year: 2018 Page: 127-133
Author(s): Vasilios Papademetriou,Eleni Geladari
Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i
Journal: Current Vascular Pharmacology
Volume: 19 Issue: 2 Year: 2021 Page: 233-240
Author(s): Olga Lamacchia,Maria Rosaria Sorrentino
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Journal: Current Diabetes Reviews
Volume: 13 Issue: 4 Year: 2017 Page: 405-423
Author(s): Matthew J. Levine
Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Journal: Current Diabetes Reviews
Volume: 14 Issue: 6 Year: 2018 Page: 509-517
Author(s): Molly G. Minze,Kayley J. Will,Brian T. Terrell,Robin L. Black,Brian K. Irons